Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
<h4>Background</h4>The proteasome inhibitor bortezomib represents an important advance in the treatment of multiple myeloma (MM). Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of cytotoxicity is not well...
Guardado en:
Autores principales: | Feng Ge, Chuan-Le Xiao, Li-Jun Bi, Sheng-Ce Tao, Sheng Xiong, Xin-Feng Yin, Li-Ping Li, Chun-Hua Lu, Hai-Tao Jia, Qing-Yu He |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/89edd93f68fc4e119593f13c6a7b02da |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Ajai Chari, et al.
Publicado: (2010) -
Systematic Synergy of Glucose and GLP-1 to Stimulate Insulin Secretion Revealed by Quantitative Phosphoproteomics
por: Jia-shu Tang, et al.
Publicado: (2017) -
Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Shansa Pranami E. Jayaweera, et al.
Publicado: (2021) -
Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
por: Melissa K. Bennett, et al.
Publicado: (2022) -
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma
por: Hector H. Huang, et al.
Publicado: (2020)